Sign In
Section Navigation
Common TitleECHO
Official Title A Phase III, Randomized, Double-blind Trial of Rilpivirine (TMC278) 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.
Phase Phase III
ClinicalTrials.gov NCT00540449
Treatments
Efavirenz
Efavirenz Sustiva

Efavirenz

Tradename:SustivaOther Names:EFVClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
,
Rilpivirine
Rilpivirine Edurant

Rilpivirine

Tradename:EdurantOther Names:RPVClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
,
Efavirenz-Tenofovir DF-Emtricitabine
Efavirenz-Tenofovir DF-Emtricitabine Atripla

Efavirenz-Tenofovir DF-Emtricitabine

Tradename:AtriplaOther Names:EFV-TDF-FTC, Efavirenz-Tenofovir disoproxil fumarate-EmtricitabineClass:Single-Tablet Regimens
,
Rilpivirine-Tenofovir DF-Emtricitabine
Rilpivirine-Tenofovir DF-Emtricitabine Complera

Rilpivirine-Tenofovir DF-Emtricitabine

Tradename:CompleraOther Names:RPV-TDF-FTC, Rilpivirine-Tenofovir disoproxil fumarate-EmtricitabineClass:Single-Tablet Regimens
Funding
IndustryTibotec Pharmaceuticals, Ireland

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.